Exact Sciences Corp(EXAS)stock report

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Cologuard test is intended for the qualitative detection of colorectal neoplasia associated DNA markers and for the presence of occult hemoglobin in human stool. It focuses on the development of additional tests for other types of cancer. It is developing a blood-based biomarker test to aid in the early detection of lung cancer in individuals with lung nodules discovered through a computerized tomography (CT) or other scan.

点评:上个月FDA批准的肝癌检测装置检测6个不同biomarkers其效果达到80% sensitivity (detecting true positives) and 90% specificity (detecting true negatives)。EXAS的市场很大,而且这种无损/微创的检测方法接受度肯定高于传统方式,是今后医学检测的发展方向。

Q3 2019(9/30/19): Cash 1161M. Loss 41M

EPS and Sales:

Date EPS % last year % last quarter
2018.12.31 -1.4251 -50.11% -44.53%
2019.3.31 -0.66 -100.00% 53.69%
2019.6.30 -0.95 -53.23% 37.00%
2019.9.30 -1.2474 -26.51% -31.31%


Date Sales % last year % last quarter
2018.12.31 454M 70.86% 45.98%
2019.3.31 162M 79.46% -64.32%
2019.6.30 362M 87.34% 123.46%
2019.9.30 581M 86.44% 60.50%


Insider Transactions:

Institution Ownership:

Total institutions: 656,no change
Shares hold: 134000k shares. no change
shares% hold: 102.99%,no change

Analyst Ratings:

Leave a Reply